Click it and Unblock the Notifications
Sai Parenterals Ltd. IPO
IPO Timeline
-
24 Mar 2026Bidding Starts
-
27 Mar 2026Bidding Ends
-
30 Mar 2026Allotment Finalization
-
2 Apr 2026Listing
About Sai Parenterals Ltd.
Our Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. We are in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets. Our Company’s portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, we have capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampoules, and vials.
Sai Parenterals Ltd. IPO Reservation
| Investors Category | Shares Offered |
|---|---|
| Anchor Investors | 31,28,485 (30%) |
| Non Institutional Investors | 15,64,244 (15%) |
| Qualified Institutional Buyers (QIBs) | 20,85,658 (20%) |
| Retail Individual Investors (RIIs) | 36,49,901 (35%) |
Sai Parenterals Ltd. Financial Information
| Year End | Revenue | PAT | Reserves & Surplus |
|---|---|---|---|
| 31 Mar 2026 | 164.99 Cr | 16.78 Cr | 464.89 Cr |
| 31 Mar 2023 | 96.98 Cr | 4.58 Cr | 24.33 Cr |
| 31 Mar 2022 | 90.03 Cr | 8.41 Cr | 17.43 Cr |
Sai Parenterals Ltd. Background
-
2001Company was incorporated as a Private Limited Company under the name of Sai Parenteral’s Private Limited.
-
2016Change in the ownership of the Company, due to acquisition of Equity Shares by our Promoters from the erstwhile promoters of the Company.
Acquired Unit-I and Unit-II.
-
2021Launch of Prefilled technology equipment in Unit-I.
-
2022Acquired Unit III and related business from Reichindia Pharma Limited. For details see “Acquisition of Business undertaking of Reichindia Pharma Limited on a slump sale basis” on page 270.
Acquired Unit IV and related business from Medreich Limited. For details see “Acquisition of Business undertaking of Medreich Limited on a slump sale basis” on page 271.
-
2023Incorporated, SP Analytics Private Limited one of our Subsidiary
Our Company achieved a turnover of ₹1,000 million
-
2024Our Company acquired 100 % shareholding of Revat Laboratories Private Limited, pursuant to which it became a wholly owned subsidiary of our Company.
-
2025Incorporated a wholly owned subsidiary, Sai Parenterals Pte. Limited in Singapore.
Acquisition of foreign step-down subsidiaries, Noumed Pharmaceuticals Pty Limited in Australia and Noumed Pharmaceuticals Limited in New Zealand.
1. Capacity expansion and upgradation of manufacturing facilities
2. Establishment of a new R&D centre
3. Repayment / prepayment of certain outstanding borrowings
4. Working capital requirements
5. Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
6. General corporate purposes
| Pricing Details | BSE | NSE |
|---|---|---|
| Issue Price | ₹ 392.00 | ₹ 392.00 |
| Open | ₹ 405.00 | ₹ 400.00 |
| Low | ₹ 400.00 | ₹ 400.00 |
| High | ₹ 416.20 | ₹ 416.00 |
| Last Trade | ₹ 406.40 | ₹ 405.70 |
1. Anil Kumar Karusala
2. Vijitha Gorrepati
3. Karusala Aruna
The Indian pharmaceutical industry is the world’s third largest by volume and was estimated at $62 billion in 2025. It is expected to grow at a CAGR of 11.2% to reach $146 billion by 2033. The Indian drug formulation market, estimated at ~$47 billion in 2025, is projected to reach $109 ... Read more
Phone no:7997991301
FAQs
When does Sai Parenterals Ltd. IPO opens and closes?
Sai Parenterals Ltd. IPO opens from 24th March to 27th March 2026.What is the size of Sai Parenterals Ltd. IPO?
The size of the Sai Parenterals Ltd. IPO is ₹408.79 Cr.What is the price range of Sai Parenterals Ltd. IPO?
The price range of Sai Parenterals Ltd. IPO is at ₹372 to ₹392 per share.What is the minimum investment and lot size required for the Sai Parenterals Ltd. IPO?
The minimum investment required is ₹14,896 and minimum lot size is 38 shares.When is Sai Parenterals Ltd. IPO listing date?
The Sai Parenterals Ltd. IPO will be listed on 2nd April 2026.What is the objective of Sai Parenterals Ltd. IPO?
1. Capacity expansion and upgradation of manufacturing facilities2. Establishment of a new R&D centre
3. Repayment / prepayment of certain outstanding borrowings
4. Working capital requirements
5. Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
6. General corporate purposes
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article
Sign in with Google